Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections

Robert A. McCready, M. Ann Bryant, John W. Fehrenbacher, Daniel J. Beckman, Arthur C. Coffey, Joel S. Corvera, David A. Hormuth, Thomas C. Wozniak

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Our purpose was to evaluate our results with CPAs in patients with infected grafts or primary arterial infection with emphasis on long-term durability of these grafts. Methods: To evaluate the long-term durability of CPAs, clinical outcomes were analyzed following their use for either graft or primary arterial infections at a single institution over a 9-y period (2000-2009). The 30-d mortality rate, 90-d mortality rate, and the cause of early mortality were determined in each case. Among those surviving 90 d, the grafts were evaluated for subsequent failure. Results: From 2000 through 2009, 51 patients with either infected prosthetic grafts (35) or primary arterial infections (15) received CPAs. One patient had infection of a previously placed thoracic allograft. Forty-three graft infections involved either the thoracic or abdominal aorta. Eleven patients presented with fulminant sepsis with systemic inflammatory response syndrome (SIRS), seven of whom died postoperatively. Eight patients presented with aorto-enteric, esophageal, or bronchial fistulae with infected prosthetic grafts. The 30-d mortality rate was 25.5% (11 deaths) seven of which occurred in patients with SIRS. The 90-d mortality rate was 41.4%. There were 10 graft failures, seven occurring in patients with aorto-enteric or bronchial fistulae all of whom had recurrent hemorrhage. The other three graft failures were due to anastomotic hemorrhage in the early postoperative period. Among those surviving 90 d, the mean follow-up was 46.4 mo (range 1-112 mo). No aneurysmal degeneration of the CPAs was noted. Only one subsequent allograft graft failure was noted among those surviving more than 90 d. Conclusions: CPAs are a suitable option in dealing with cardiovascular infections. Patients with enteric or bronchial fistulae are a difficult group to treat perhaps because of ongoing contamination of the allograft. The operative mortalities are largely determined by patient comorbidities (SIRS). Subsequent degeneration or infection of the CPAs is rare.

Original languageEnglish (US)
JournalJournal of Surgical Research
Volume168
Issue number1
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Allografts
Transplants
Infection
Bronchial Fistula
Systemic Inflammatory Response Syndrome
Mortality
Therapeutics
Cardiovascular Infections
Hemorrhage
Esophageal Fistula
Abdominal Aorta
Thoracic Aorta
Postoperative Period
Comorbidity
Sepsis
Thorax

Keywords

  • aorto-bronchial fistula
  • aorto-esophageal fistula
  • cryopreserved allografts
  • graft infections
  • infected aneurysms
  • primary arterial infection

ASJC Scopus subject areas

  • Surgery

Cite this

McCready, R. A., Bryant, M. A., Fehrenbacher, J. W., Beckman, D. J., Coffey, A. C., Corvera, J. S., ... Wozniak, T. C. (2011). Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections. Journal of Surgical Research, 168(1). https://doi.org/10.1016/j.jss.2010.09.026

Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections. / McCready, Robert A.; Bryant, M. Ann; Fehrenbacher, John W.; Beckman, Daniel J.; Coffey, Arthur C.; Corvera, Joel S.; Hormuth, David A.; Wozniak, Thomas C.

In: Journal of Surgical Research, Vol. 168, No. 1, 01.06.2011.

Research output: Contribution to journalArticle

McCready, RA, Bryant, MA, Fehrenbacher, JW, Beckman, DJ, Coffey, AC, Corvera, JS, Hormuth, DA & Wozniak, TC 2011, 'Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections', Journal of Surgical Research, vol. 168, no. 1. https://doi.org/10.1016/j.jss.2010.09.026
McCready, Robert A. ; Bryant, M. Ann ; Fehrenbacher, John W. ; Beckman, Daniel J. ; Coffey, Arthur C. ; Corvera, Joel S. ; Hormuth, David A. ; Wozniak, Thomas C. / Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections. In: Journal of Surgical Research. 2011 ; Vol. 168, No. 1.
@article{899387709dd74b708d7b3f5c0b1b0449,
title = "Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections",
abstract = "Objective: Our purpose was to evaluate our results with CPAs in patients with infected grafts or primary arterial infection with emphasis on long-term durability of these grafts. Methods: To evaluate the long-term durability of CPAs, clinical outcomes were analyzed following their use for either graft or primary arterial infections at a single institution over a 9-y period (2000-2009). The 30-d mortality rate, 90-d mortality rate, and the cause of early mortality were determined in each case. Among those surviving 90 d, the grafts were evaluated for subsequent failure. Results: From 2000 through 2009, 51 patients with either infected prosthetic grafts (35) or primary arterial infections (15) received CPAs. One patient had infection of a previously placed thoracic allograft. Forty-three graft infections involved either the thoracic or abdominal aorta. Eleven patients presented with fulminant sepsis with systemic inflammatory response syndrome (SIRS), seven of whom died postoperatively. Eight patients presented with aorto-enteric, esophageal, or bronchial fistulae with infected prosthetic grafts. The 30-d mortality rate was 25.5{\%} (11 deaths) seven of which occurred in patients with SIRS. The 90-d mortality rate was 41.4{\%}. There were 10 graft failures, seven occurring in patients with aorto-enteric or bronchial fistulae all of whom had recurrent hemorrhage. The other three graft failures were due to anastomotic hemorrhage in the early postoperative period. Among those surviving 90 d, the mean follow-up was 46.4 mo (range 1-112 mo). No aneurysmal degeneration of the CPAs was noted. Only one subsequent allograft graft failure was noted among those surviving more than 90 d. Conclusions: CPAs are a suitable option in dealing with cardiovascular infections. Patients with enteric or bronchial fistulae are a difficult group to treat perhaps because of ongoing contamination of the allograft. The operative mortalities are largely determined by patient comorbidities (SIRS). Subsequent degeneration or infection of the CPAs is rare.",
keywords = "aorto-bronchial fistula, aorto-esophageal fistula, cryopreserved allografts, graft infections, infected aneurysms, primary arterial infection",
author = "McCready, {Robert A.} and Bryant, {M. Ann} and Fehrenbacher, {John W.} and Beckman, {Daniel J.} and Coffey, {Arthur C.} and Corvera, {Joel S.} and Hormuth, {David A.} and Wozniak, {Thomas C.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.jss.2010.09.026",
language = "English (US)",
volume = "168",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term results with cryopreserved arterial allografts (CPAs) in the treatment of graft or primary arterial infections

AU - McCready, Robert A.

AU - Bryant, M. Ann

AU - Fehrenbacher, John W.

AU - Beckman, Daniel J.

AU - Coffey, Arthur C.

AU - Corvera, Joel S.

AU - Hormuth, David A.

AU - Wozniak, Thomas C.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Objective: Our purpose was to evaluate our results with CPAs in patients with infected grafts or primary arterial infection with emphasis on long-term durability of these grafts. Methods: To evaluate the long-term durability of CPAs, clinical outcomes were analyzed following their use for either graft or primary arterial infections at a single institution over a 9-y period (2000-2009). The 30-d mortality rate, 90-d mortality rate, and the cause of early mortality were determined in each case. Among those surviving 90 d, the grafts were evaluated for subsequent failure. Results: From 2000 through 2009, 51 patients with either infected prosthetic grafts (35) or primary arterial infections (15) received CPAs. One patient had infection of a previously placed thoracic allograft. Forty-three graft infections involved either the thoracic or abdominal aorta. Eleven patients presented with fulminant sepsis with systemic inflammatory response syndrome (SIRS), seven of whom died postoperatively. Eight patients presented with aorto-enteric, esophageal, or bronchial fistulae with infected prosthetic grafts. The 30-d mortality rate was 25.5% (11 deaths) seven of which occurred in patients with SIRS. The 90-d mortality rate was 41.4%. There were 10 graft failures, seven occurring in patients with aorto-enteric or bronchial fistulae all of whom had recurrent hemorrhage. The other three graft failures were due to anastomotic hemorrhage in the early postoperative period. Among those surviving 90 d, the mean follow-up was 46.4 mo (range 1-112 mo). No aneurysmal degeneration of the CPAs was noted. Only one subsequent allograft graft failure was noted among those surviving more than 90 d. Conclusions: CPAs are a suitable option in dealing with cardiovascular infections. Patients with enteric or bronchial fistulae are a difficult group to treat perhaps because of ongoing contamination of the allograft. The operative mortalities are largely determined by patient comorbidities (SIRS). Subsequent degeneration or infection of the CPAs is rare.

AB - Objective: Our purpose was to evaluate our results with CPAs in patients with infected grafts or primary arterial infection with emphasis on long-term durability of these grafts. Methods: To evaluate the long-term durability of CPAs, clinical outcomes were analyzed following their use for either graft or primary arterial infections at a single institution over a 9-y period (2000-2009). The 30-d mortality rate, 90-d mortality rate, and the cause of early mortality were determined in each case. Among those surviving 90 d, the grafts were evaluated for subsequent failure. Results: From 2000 through 2009, 51 patients with either infected prosthetic grafts (35) or primary arterial infections (15) received CPAs. One patient had infection of a previously placed thoracic allograft. Forty-three graft infections involved either the thoracic or abdominal aorta. Eleven patients presented with fulminant sepsis with systemic inflammatory response syndrome (SIRS), seven of whom died postoperatively. Eight patients presented with aorto-enteric, esophageal, or bronchial fistulae with infected prosthetic grafts. The 30-d mortality rate was 25.5% (11 deaths) seven of which occurred in patients with SIRS. The 90-d mortality rate was 41.4%. There were 10 graft failures, seven occurring in patients with aorto-enteric or bronchial fistulae all of whom had recurrent hemorrhage. The other three graft failures were due to anastomotic hemorrhage in the early postoperative period. Among those surviving 90 d, the mean follow-up was 46.4 mo (range 1-112 mo). No aneurysmal degeneration of the CPAs was noted. Only one subsequent allograft graft failure was noted among those surviving more than 90 d. Conclusions: CPAs are a suitable option in dealing with cardiovascular infections. Patients with enteric or bronchial fistulae are a difficult group to treat perhaps because of ongoing contamination of the allograft. The operative mortalities are largely determined by patient comorbidities (SIRS). Subsequent degeneration or infection of the CPAs is rare.

KW - aorto-bronchial fistula

KW - aorto-esophageal fistula

KW - cryopreserved allografts

KW - graft infections

KW - infected aneurysms

KW - primary arterial infection

UR - http://www.scopus.com/inward/record.url?scp=79955610408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955610408&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2010.09.026

DO - 10.1016/j.jss.2010.09.026

M3 - Article

C2 - 21109265

AN - SCOPUS:79955610408

VL - 168

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -